BDBM279842 US10028960, Example 2-6::US11110095, Example 2-6

SMILES COc1cc(Nc2cc(CO)[nH]n2)nc(n1)N(C)[C@H]1C[C@@H]2CCC[C@H](C1)N2CC1(CC1)C#N

InChI Key

Data  8 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 279842   

TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279842(US10028960, Example 2-6 | US11110095, Example 2-6)
Affinity DataKi:  0.550nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279842(US10028960, Example 2-6 | US11110095, Example 2-6)
Affinity DataKi:  0.550nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279842(US10028960, Example 2-6 | US11110095, Example 2-6)
Affinity DataKi:  0.550nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279842(US10028960, Example 2-6 | US11110095, Example 2-6)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279842(US10028960, Example 2-6 | US11110095, Example 2-6)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279842(US10028960, Example 2-6 | US11110095, Example 2-6)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279842(US10028960, Example 2-6 | US11110095, Example 2-6)
Affinity DataKi:  5.5nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM279842(US10028960, Example 2-6 | US11110095, Example 2-6)
Affinity DataKi:  5.5nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent